Replies to post #4462 on GTC Biotherapeutics (fka GTCB)

[kayamalo1]

Agreed that macugen/lucentis is an exception and that Lucentis is far superior
but to clarify: Macugen can improve acuity and may have a better safety profile for long term

Please see:
<<6% of patients receiving MACUGEN 0.3 mg (18/294) gained 3 15 letters of vision versus 2% of patients receiving usual care (6/296) (secondary end point P<.05)1,2>>
Gragoudas ES, et al. N Engl J Med 2004;351:2805-16

I just brought up macugen/lucentis to mention an exception as a caution because the "first in" principle most likely helped to inform OSI in its disastrous acquisition of eyet